Liverpool ChiroChem Ltd. (LCC), an investee company within Deepbridge Capital's Life Science EIS fund, has recently raised £2.2 million of investment from a panel of regional investors to expand its team and continue its global operation from within the United Kingdom. Deepbridge Capital contributed £1.2m to this round. 

Liverpool ChiroChem is a chemical technology innovator, on a mission to accelerate new chemical entity (NCE) discovery and development through improved access to 3D chemical space. LCC was founded in 2014 and has operations in the UK and China, serving a global customer base within the life science sector. 

LCC will use the money raised to increase its presence in the US, which currently accounts for 80 per cent of its customers and revenue. This will coincide with additional hires across the firm, including in business development, production and operations, with 50 per cent headcount growth targeted by the end of 2023. 

Paul Colbon, CEO & Co-Founder of Liverpool ChiroChem Ltd., said: 

"With this latest investment, we can now ramp up production and delivery of our specialist chemical components, and I’m incredibly proud that we’ll be doing this from the North West, a region which has given us so much." 

Paul Colbon, CEO & Co-Founder of Liverpool ChiroChem Ltd. was recently featured within the Deepbridge Discovery Podcast. To watch this episode, click here or you can listen to by clicking here. 

Dr. Savvas Neophytou, Partner & Chief Investment Officer at Deepbridge Capital, commented: 

"We're delighted that the GMC Life Sciences Fund By Praetura and Maven continue to work with us to support LCC; a company which excellently showcases the North West's life sciences expertise on a global stage. It's great to have another North West-based fund that compliments the Deepbridge Life Sciences EIS fund." 

Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).